Scil Proteins operates two business units: Scil Proteins Pharma and Scil Proteins Production.
Scil
Proteins Pharma
Scil
Proteins Pharma proprietary Affilin® platform allows the generation of innovative
biopharmaceuticals. Affilin® therapeutics
will elicit beneficial effects where conventional therapeutic approaches
proved to be inefficacious.
For its
proprietary product pipeline Scil Proteins Pharma applies the Affilin®platform in the
core indications inflammation/infectious diseases and oncology.
The Affilin®technology is fully patent protected and allows freedom-to-operate for numerous
disease relevant targets.
Scil
Proteins Pharma is actively looking for opportunities to partner its Affilin®drug
discovery platform with the biotechnology and pharmaceutical industry.
Scil
Proteins Production
Scil
Protein Production provides full up- and downstream process development for the
manufacturing of recombinant proteins in microbial expression systems. Special
expertise in re-folding allows a straight forward set-up of high-yield
production processes.
The Non-GMP
process development and pre-manufacturing comprises production of pilot
batches from research grade to quality meeting IND/IMPD requirements.
In
its GMP facilities Scil Proteins Production provides capacities for
the manufacturing of API for clinical development and market supply.
